Ordering
Available Variants5 mg
CHA.30048-5mg
Price
€182.40
Available – Dispatch in 14 days
25 mg
CHA.30048-25mg
Price
€667.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.30048-5mg | €182.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.30048-25mg | €667.20 |
≥98% (HPLC), powder, BET bromodomain protein inhibitor
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C23H25ClN4O2S |
|---|---|
| CAS Number | 1268524-70-4 |
| Molecular Weight | 456.99 |
| UNSPSC Code | 41106609 |
| PubChem Substance ID | 329825941 |
| NACRES | NA.77 |
| MDL number | MFCD22683748 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
(+)-JQ1, also known as (R)-JQ1, is a small molecule inhibitor with a CAS number of 1268524-70-4. It has been identified as a potent and selective inhibitor of the bromodomain and extra-terminal domain (BET) family of proteins. The compound has been shown to bind to the acetyl-lysine recognition pocket of BET proteins, thereby blocking their interaction with chromatin and inhibiting the transcriptional activation of target genes. (+)-JQ1 has been used as a tool compound to study the role of BET proteins in various biological processes, including transcriptional regulation, cell cycle progression, and apoptosis. Its inhibitory activity has also been explored in the context of various diseases, including cancer, inflammation, and cardiovascular disease, where BET proteins have been implicated in disease pathogenesis. Further research is needed to fully elucidate the therapeutic potential of (+)-JQ1.
